Novan Therapeutics, developer of investigational acne product SB204, has announced the addition of two executives from the dermatology industry to the its leadership team. Richard Peterson, formerly of Medicis International, has joined the company as Chief Financial Officer and Brian Johnson, formerly of Galderma and Medicis International, as Chief Commercial Officer. Peterson will be responsible for the company's financial operations, investor relations and other corporate functions. Johnson will lead Novan’s newly focused commercialization efforts including sales, marketing and managed care for the company's dermatology products.
“Novan’s success with SB204 has demonstrated the potential of a platform technology that promises to bring sustainable innovation into dermatology as we aggressively expand the pipeline into other indications,” said Peterson. “I am excited for the opportunity to use my industry experience and financial leadership to create value for the company's shareholders.”
“It is rare when you are given the opportunity to build something special from the ground up,” said Johnson. “ I am thrilled to be joining the Novan team as we turn the corner towards commercialization of SB204 for the treatment of acne and look forward to helping create a preeminent dermatology company in the United States.”
